Table 4 |
|||||
|
Health status measured at baseline (T0), end of intervention (T1), and 12 weeks follow-up (T2) (n = 13) |
|||||
|
T0 |
T1 |
p-value (T0-T1) |
T2 |
p-value (T0-T2) |
|
|
|
|||||
|
HAQ (0-3) |
0.5 (0.0-1.5) |
0.5 (0.0-1.2) |
0.72 |
0.5 (0.0-1.5) |
0.34 |
|
Fatigue (0-100) |
27 (5 - 89) |
28 (3 - 81) |
0.55 |
25 (6 - 74) |
0.70 |
|
Muscle pain (0-100) |
30 (1 - 60) |
25 (2 - 69) |
0.92 |
23 (2 - 61) |
0.88 |
|
Fear of falling (0-100) |
14 (0 -76) |
21 (2 - 71) |
0.75 |
33 (10-95) |
0.13 |
|
SF-36 (0-100) |
|||||
|
Vitality |
45 (15 - 80) |
55 (35 - 70) |
0.26 |
50 (25 - 70) |
0.59 |
|
Pain |
51 (0 - 84) |
62 (41 - 84) |
0.05 |
42 (22 - 100) |
0.17 |
|
General health |
52 (35 - 82) |
50 (32 - 87) |
0.96 |
47 (35 - 97) |
0.92 |
|
Mental health |
80 (40 - 92) |
76 (36 - 92) |
0.68 |
76 (56 - 92) |
0.59 |
|
Physical functioning |
75 (25 - 95) |
70 (30 - 95) |
0.72 |
75 (25 - 95) |
0.91 |
|
Social functioning |
75 (12 - 100) |
75 (25 - 100) |
0.03 |
62 (12 - 100) |
0.22 |
|
Role emotional |
100 (0 - 100) |
100 (33 - 100) |
0.23 |
67 (0 - 100) |
0.86 |
|
Role physical |
50 (0 - 100) |
75 (0 - 100) |
0.19 |
25 (0 - 100) |
0.91 |
|
Self-efficacy (10-100) |
|||||
|
Pain |
NA |
70 (18 - 100) |
NA |
62 (18 - 86) |
0.45* |
|
Function |
89 (54 - 100) |
88 (28 - 99) |
0.40 |
90 (61 - 100) |
0.22 |
|
Symptoms |
75 (35 - 90) |
75 (42 - 100) |
0.45 |
78 (57-97) |
0.13 |
|
|
|||||
|
Values are median (range). *T1 versus T2 NA = not assessed HAQ = Health Assessment Questionnaire SF-36 = Short Form Health Survey 36 |
|||||
|
Uhlig et al. BMC Musculoskeletal Disorders 2010 11:43 doi:10.1186/1471-2474-11-43 |
|||||
